Supplementary Figures S1-S4

Airway mucus drive severity and mortality in diverse chronic lung diseases. The Jagged-1/Notch pathway controls the balance of ciliated vs mucous cells, but targeting the pathway systemically carries the risk of side effects. Here we developed a novel, Anticalin-derived, pulmonary-delivered Jagged-1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Heinzelmann, Katharina, Fysikopoulos, Athanasios, Jean Jaquin, Thomas, K. Peper-Gabriel, Janet, Hansbauer, Eva-Maria, Grüner, Stefan, Prassler, Josef, Wurzenberger, Claudia, G. C. Kennedy, Joseph, Y. Snead, Jazmin, Alexander Wrennall, Joe, Heinig, Kristina, Wurzenberger, Cornelia, Bel Aiba, Rachida-Siham, Tarran, Robert, Livraghi-Butrico, Alessandra, F. Fitzgerald, Mary, P. Anderson, Gary, Rothe, Christine, Matschiner, Gabriele, A. Olwill, Shane, Hagner, Matthias
Format:	Bild
Sprache:	eng
Schlagworte:	Other biomedical and clinical sciences not elsewhere classified
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Airway mucus drive severity and mortality in diverse chronic lung diseases. The Jagged-1/Notch pathway controls the balance of ciliated vs mucous cells, but targeting the pathway systemically carries the risk of side effects. Here we developed a novel, Anticalin-derived, pulmonary-delivered Jagged-1 antagonist, to inhibit airway mucus hyperproduction and obstruction in chronic lung diseases. Our preclinical data demonstrate the effectiveness of these antagonists in diminishing secretory cell and mucus levels, and alleviating hallmarks of mucus obstruction.
DOI:	10.6084/m9.figshare.27138645